BioCatalystWatch
GENBWorkspace / GENB / OverviewCompany library
Generate Biomedicines, Inc. logo

Generate Biomedicines, Inc.

Generate Biomedicines, Inc. (GENB)

Website

Price
Market cap
Next catalystExpected 2027GB-4362 with enfortumab vedotin and pembrolizumab · Phase 1 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

GB-4362GB-4362 with enfortumab vedotin and pembrolizumab

Free MMAE

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

GB-4362GB-4362 with enfortumab vedotin and pembrolizumab

Free MMAE

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

GB-4362

Free MMAE

GB-0895

TSLP

PreINDP1P2P3FilingApproved
GB-0895

TSLP

PreINDP1P2P3FilingApproved
GB-7624

IL-13

PreINDP1P2P3FilingApproved
GB-7624

IL-13

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

GENB PR & News

PR & News

GENB SEC archive